Skip to content Skip to navigation

Drugs and Generics

Bottle of Revlimid Pills

Celgene Corporation is paying $55 million to settle antitrust class actions about its drugs Thalomid and Revlimid. The complaints alleged that the company acted to keep generics of the drugs off the market for a time, forcing consumers to pay more for the drugs than they would have with open market competition.

Santarus Glumetza Label

What’s a fair price for a thirty-day supply of the extended-release diabetes medicine Glumetza—generic name metformin? Is it $55 or $2,200? The complaint for this class action alleges that a number of companies conspired to limit the entry of generic versions of Glumetza to the market. The defendants in this antitrust suit are Bausch Health Compaines, Inc. (formerly Valeant Pharmaceuticals International), Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Santarus, Inc., Assertio Therapeutics, Inc. (formerly Depomed, Inc.), Lupin Pharmaceuticals, Inc., and Lupin, Ltd.

Front Label of Provigil Container

An antitrust class action and an antitrust case brought by the California Attorney General (CAAG) on the same topic are being settled at the same time. The suits claim that drug companies conspired to keep prices of the original drug Provigil high by delaying the introduction of generics and (in the CAAG suit) of Nuvigil.

Ranbaxy Building

The complaint for this class action alleges that Ranbaxy Laboratories, Ltd. took advantage of Food and Drug Administration (FDA) rules on approvals for generic drugs. The complaint says it claimed first-to-file rights for generics of popular drugs even when it had not yet sufficiently developed the generics, in order to block others from doing so. The complaint claims violations of antitrust and anti-racketeering (RICO) laws.

Bottles of Solodyn

The final two defendants in a class action have agreed to settle a class action alleging that a group of companies engaged in anti-competitive behavior. The complaint alleges that Medicis Pharmaceutical Corp.(“Medicis”), Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. unlawfully settled patent lawsuits covering the drug Solodyn.